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ABSTRACT
The inhibitory activities of selected cyclic urea and carbamate derivatives (1–13) toward a-glucosidase
(a-Gls) in in vitro assay were examined in this study. All examined compounds showed higher inhibitory
activity (IC50) against a-Gls compared to standard antidiabetic drug acarbose. The most potent was benzyl
(3,4,5-trimethoxyphenyl)carbamate (12) with IC50¼ 49.85±0.10mM. In vitro cytotoxicity of the investigated
compounds was tested on three human cancer cell lines HeLa, A549 and MDA-MB-453 using MTT assay.
The best antitumour activity was achieved with compound 2 (trans-5-phenethyl-1-phenylhexahydro-1H-imi-
dazo[4,5-c]pyridin-2(3H)-one) against MDA-MB-453 human breast cancer cell line (IC50¼ 83.41±1.60mM).
Cyclic ureas and carbamates showed promising anti-a-glucosidase activity and should be further tested as
potential antidiabetic drugs. The PLS model of preliminary QSAR study indicated that, in planing the future
synthesis of more potent compounds, the newly designed should have the substituents capable of polar
interactions with receptor sites in various positions, while avoiding the increase of their lipophilicity.
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Diabetes mellitus type 2 (DMT2) is an endocrine disease of global
proportions which is currently affecting 1 out of 12 adults in the
world, with still increasing prevalence1. World Health Organization
(WHO) declared this worldwide health problem as an epidemic
disease to be the only noninfectious disease with such categoriza-
tion2. This deadly disease is associated with numerous side effects
such as impairment of functions of kidneys, heart, eye and ner-
vous system affecting carbohydrate, protein and fat metabolism3.
The main classes of oral antidiabetic drugs accessible today for
DMT2 vary in their chemical composition, modes of action, safety
profiles and tolerability4. Both the insulin resistance and the
decrease in insulin production over time, allow the treatment of
people suffering from DMT2 with a wide range of drugs that are
available on the market5. Insulin, sulfonylureas, the metiglinides,
insulin sensitizers, biguanides and a-glucosidase inhibitors belong
to the group of traditional antidiabetics developed during the
twentieth century2,6 while the newer drugs such as GLP-1 analogs,
DPP-VI inhibitors, amylin analogs and SGLT2 inhibitors emerged
during the past decade2,7.
a-Glucosidase (a-Gls) inhibitors postpone digestion and absorp-
tion of intestinal carbohydrate3,4. They are agents convenient for
the reduction of postprandial hyperglycemia by suppressing the
absorption of glucose, hence being effective in the treatment of
T2 diabetes and obesity. Besides, the current interest in a-Gls
inhibitors has been extended to a broad range of diseases includ-
ing lysosomal storage disorders and cancer, and HIV infection8,9.
Amongst the various types of a-Gls inhibitors, disaccharides,
iminosugars, carbasugars, thiosugars, and non-sugar derivatives
have received great attention9. Since 1990s, acarbose (GlucobayVR ,
PrecoseVR , PrandaseVR ), voglibose (BasenVR ), and miglitol (GlysetVR )
(Figure 1) have been used for the treatment of diabetes10.
However, complicated multi-step synthetic procedures imposed a
need for the synthesis of compounds with no structural similarity
to the above compounds. Such compounds represent a new class
of inhibitors that are of major interest. The elucidation of their
mechanism of action may add new insights in the search for new
therapeutic agents9. Most recently, benzimidazole derivatives,
dihydropyrano[2,3-c]pyrazoles have been evaluated as a-Gls inhibi-
tors11–13. A series of indoline carbamate and indolinylpyrimidine
derivatives have been discovered as potent GPR119 agonists, and
are expected to serve as novel anti-diabetic agents14.
Due to the importance of antidiabetic agents and their role in
controlling diabetes-related mortality, the search for newer antidia-
betic drugs continues. Among the others, heterocyclic molecules
with antidiabetic activity have a place in the most perspective
fields of the research2.
Previous work in our laboratory resulted in the development of
the one-pot procedure for the Hofmann rearrangement of aro-
matic or aliphatic amides, which led to the synthesis of a series of
carbamates and cyclic ureas15. With regard to the synthesis of
these classes of compounds, different protocols have been
reported in the literature16,17. Carbamate derivatives with a recog-
nizable –O–CO–NH– moiety encompass multiple applications in
bioorganic and medicinal chemistry18–24. Cyclic ureas are synthet-
ically useful intermediates, particularly as precursors to
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pharmacologically active imidazoles15. Moreover, in the 1990s
these compounds have been a part of intensive researches on the
human immunodeficiency virus (HIV – the causative agent of
AIDS), which revealed that certain derivatives of cyclic ureas act as
potent HIV protease inhibitors25,26.
The results of the selected cyclic urea and carbamate deriva-
tives for the inhibitory activity against a-Gls are being reported
herein. In addition, in vitro cytotoxicity of the examined com-
pounds was tested toward three human cancer cell lines: cervix
adenocarcinoma (HeLa), non-small cell lung carcinoma (A549) and
human breast cancer (MDA-MB-453). QSAR analysis was
attempted on activity against a-glucosidase by applying PLS
(Partial Least Square) regression analysis. The interpretation of
descriptors which are included in PLS model can help us in better




Unless stated otherwise, all the commercially available reagents
and solvents were used as supplied. a-Gls from Saccharomyces cer-
evisiae, RPMI 1640 (product number R8755), p-nitrophenyl a-D-glu-
copyranoside (PNP-G), acarbose, fetal bovine serum (FCS),
dimethyl sulfoxide (DMSO), hepes, ethidium bromide, sodium
dodecyl sulfate (SDS), acridine orange, disodium hydrogen phos-
phate dihydrate, sodium dihydrogen phosphate dihydrate and
thiazolyl blue tetrazolium bromide (MTT) were purchased from
Sigma-Aldrich (St. Louis, MO). Trypsin and phosphate buffered
saline (PBS) were obtained from Institute of Virology, Vaccines and
Sera "Torlak", Belgrade, Serbia.
General procedure for the preparation of cyclic ureas and
carbamates
Cyclic urea (1–5) and carbamate derivatives (6–13) were synthe-
sized by a novel procedure described in our previous paper15.
Anti a-glucosidase activity
Anti-a-Gls activity of compounds was determined using an a-Gls
inhibitory activity test described by McCue et al. with some modi-
fication27. The enzyme solution was set at 400mU/mL of a-Gls in a
0.1M phosphate buffer (pH¼ 6.8). For each well we used 50mL of
the tested compounds in DMSO, diluted in a 0.1M phosphate
buffer (pH¼ 6.8). The final concentrations of the extracts in each
well were 166.67, 83.33, 41.67, 20.83, 10.42, 5.21 mM. In 96-well
plates, 50 mL of extract dilutions was preincubated with 50mL of
enzyme solution for each well at 37 C for 15min. The reaction
was started by adding 50 mL of substrate solution, p-nitrophenyl
a-D-glucopyranoside (1.5mg/mL PNP-G in phosphate buffer) and
after measuring absorbance A1 at 405 nm the solution was incu-
bated at 37 C for 15min. Second absorbance A2 was measured at
405 nm. Acarbose was used as a positive control. The percent of
the enzyme inhibition was calculated as 100 (A2S–A1S)/
(A2B–A1B), A1B, A2B and A1S, A2S representing the absorbance of
the blank (phosphate buffer, DMSO, enzyme dilution, and PNP–G
dilution) and sample, respectively. The experiments were con-
ducted in duplicate and IC50 value (estimated concentration of
compounds that caused 50% inhibition of a-Gls activity) was
determined using linear regression analysis.
MTT assay
Cytotoxic activity
Incubation of the cultures was performed according to the litera-
ture procedure28. Target cells HeLa, cervix adenocarcinoma cell
line (2000 cells per well), A549, non-small cell lung carcinoma cell
line (5000 cells per well) and MDA-MB-453 human breast cancer
cell line (3000 cells per well) were seeded into 96-well plate.
Twenty-four hours later different concentrations of investigated
compounds were added to the wells, except for the control cells
to which a nutrient medium was added. The final concentrations
range was 1–200 mM (12.50, 25, 50, 100, and 200mM). The final
concentration of DMSO solvent never exceeded 0.5%, which was
non-toxic to the cells. All concentrations were set up in triplicate.
Nutrient medium with corresponding concentrations of investi-
gated compounds, but without cells, was used as a blank, also in
triplicate. The cultures were incubated for 72 h.
Determination of cell survival The effect of the investigated com-
pounds on cancer cell survival was determined by the microcul-
ture tetrazolium test (MTT) according to Mosmann29 with
modification by Ohno and Abe30, 72 h after the addition of the
compounds, as previously described28. All experiments were done
in triplicate.
Morphological evaluation of cell death After 24 h of seeding
80 000 HeLa cells per well, they were treated with compound dilu-
tions of IC50 and 2 IC50 in control only nutrient medium was
added. After another 24 h of incubation cells were stained with
acridine orange AO and ethidium bromide EB (3lg/mLAO þ10 lg/
mL EB in PBS), then visualized under a fluorescence microscope
(Carl Zeiss, Oberkochen, Germany) PALM MicroBeam with Axio
Observer.Z1 using AxioCam MRm (filters Alexa 488 and 568), as
described in literature31.
Calculation of molecular descriptors
All structures were built using the Maestro 10.1 from Schr€odinger
Suite 2015-1 (Maestro, version 10.1, Schr€odinger, LLC, New York,
NY). QikProp version 4.3 (QikProp, version 4.3, Schr€odinger, LLC,
New York, NY) was used for the calculation of physically significant
molecular descriptors and pharmaceutically relevant properties.
Single-point calculations using the RM1 method32 from
Semiempirical NDDO module of Scrodinger Suite 2015-1 was used
for semiempirical parameters. The calculated molecular descriptors
Figure 1. a-Gls inhibitors used as antidiabetic drugs.
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which are used in final PLS regression analysis are given in Table
S1 (Supplemental Information).
Multivariate statistical analysis and modelling
PLS has been performed using a demo version of PLS_Toolbox
statistical package (Eigenvectors, v. 5.7) for MATLAB version
7.4.0.287 (R2007a) (MathWorks, Natick, MA). The data were auto-
scaled before building the model in order to prevent variables
with larger magnitude to prevail in the final model. The PLS
method calculates latent variables for both independent and
dependent variable matrices plus a relationship between them.
Validation of the models was performed using the leave-one-out
cross-validation procedure.
The quality of the regression fits was monitored with the R2cal,
(cumulative sum of squares of the Ys explained by all extracted
components) and R2CV (cumulative fraction of the total variation of
the Ys that can be predicted by all extracted components). These
values have to be as high as possible, and with root mean-square
errors of calibration and cross-validation, RMSEC and RMSECV,
respectively, have to be as low as possible, with the lowest differ-
ence between them. Low value of RMSEC is desirable but if the
high values of RMSECV are present at the same time, it indicates
the poor predictability of the calibration model33.
Results and discussion
The carbamate and urea are important chemical moieties which
can be seen in the molecular scaffold of a large number of bio-
logically active molecules. Continuing our interest in carbamate
and cyclic urea derivatives, the 13 compounds from our
“laboratory collection”15 depicted in Figure 2, were selected for
their biological evaluation. Upon the attentive survey of literature,
we concluded that data on anti-a-Gls and antiproliferative activ-
ities of compounds 1–13 cannot be found in literature.
These derivatives were synthesised by using the modified
Hofmann rearrangement method, as we recently reported15.
Briefly, b-amino carboxamides 1a–5a diastereoselectively yielded
cyclic ureas 1–5, while various aliphatic and aromatic carboxa-
mides 6a–13a were converted to the corresponding methyl or
benzyl carbamates 6–13, using N-bromoacetamide and LiOH.H2O
in MeOH or BnOH.
Anti-a-Gls activity
The anti-a-Gls activity study showed that tested compounds
expressed significant activity (Table 1). The IC50 values of the com-
pound concentrations were calculated from dose response curves
after absorbances were read and blanks subtracted. All 13 com-
pounds showed better anti-a-Gls activity than standard antidia-
betic drug acarbose. IC50 ranged from 49.85 ± 0.10 mM for
benzyl(3,4,5-trimethoxyphenyl)carbamate (12) to 104.06 ± 0.65mM
for cis 5-phenethyl-1-phenylhexahydro-1H-imidazo[4,5-c]pyridin-
2(3H)-one (1). IC50 for acarbose was 121.01 ± 12.18mM. The results
indicated that studied compounds could be potentially used to
control postprandial hyperglycemia.
In vitro cytotoxic assay
In respect to recent findings about SAR and anticancer activities of
urea derivatives34–36, in vitro cytotoxicity of compounds 1–13 was
additionally tested towards selected human cancer cell lines: cervix
adenocarcinoma HeLa, non-small cell lung carcinoma A549, and
human breast carcinoma MDAMB-453. The cell survival rate was
determined by MTT test, after 72 h of exposure to com-
pounds28–30. IC50 was defined as the concentration of the com-
pound inhibiting cell survival rate by 50%, compared with a
vehicle-treated control cells. Cytotoxic activities of compounds 2,
8, 11 and 12, as the most active ones, are shown in Table 2, while
Figure 3 depicts the cytotoxic curves from MTT assay showing the
survival of HeLa, A549 and MDA-MB-453, cell grown for 72 h in
the presence of increasing concentrations of complexes. Trans-5-
phenethyl-1-phenylhexahydro-1H-imidazo[4,5-c]pyridin-2(3H)-one
(2) showed the best cytotoxic activity (IC50) against MDA-MB-453
and A549 cell lines, with 83.41 ± 1.61mM and 110.69 ± 0.85 mM,
respectively. The most potent against HeLa cells was the com-
pound 12 with the IC50¼ 138.74 ± 8.83mM. Generally, the cytotoxic
Figure 2. Structures of cyclic urea 1–5 and carbamate 6–13 derivatives.
Table 1. IC50 values of anti-a-Gls activity of the
compounds 1–13.
Compound IC50 lM
1 104.06 ± 0.65
2 63.03 ± 2.12
3 67.59 ± 1.90
4 68.66 ± 3.02
5 67.63 ± 0.27
6 76.02 ± 5.66
7 83.46 ± 14.21
8 71.74 ± 2.90
9 77.61 ± 2.27
10 99.48 ± 0.16
11 70.41 ± 5.21
12 49.85 ± 0.10
13 75.52 ± 8.11
acarbose 121.01 ± 12.18
Results are expressed as mean ± standard
deviation.
Table 2. IC50 values (lM) of tested compounds against malignant cell lines.
IC50
compounds HeLa A549 MDA-MB-453
2 155.63 ± 31.75 110.69 ± 0.85 83.41 ± 1.60
8 158.29 ± 6.04 155.83 ± 0.70 112.42 ± 4.91
11 194.44 ± 1.44 200.00 ± 2.37 163.59 ± 3.93
12 138.74 ± 8.28 180.13 ± 2.57 107.63 ± 4.95
Results are expressed as mean ± standard deviation.
#The other tested compounds didn’t exhibit cytotoxic activity (the highest tested
concentration was 200 lM).
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activities of these four compounds were considered to be moder-
ate to low. All other compounds from the examined series were
inactive regarding all three studied cell lines, meaning they did
not exhibit cytotoxic activities as the IC50 was higher than the
highest concentration tested (200mM; data not shown).
The most active compounds (2, 8, 11 and 12) were further
tested to evaluate cell death type on the HeLa cells under the
fluorescent microscope. Morphological changes were observed
after cells were stained with acridine orange and ethidium-brom-
ide. Acridine orange can penetrate into the living cells and emits
green fluorescence, while ethidium-bromide enters the cells after
cell membrane damage and emits red fluorescence. The changes
of the cells morphology after 24 hours of treatment of IC50 and
2 IC50 dilutions of compounds 2, 8, 11 and 12, as well as
untreated control are shown on the Figure 4. Observed control
cells are with unchanged morphology, stained green. Morphology
of the cells treated with IC50 dilution of the compounds 2, 8, 11
and 12 (left side of the image) was changed, and late apoptotic
signs can be observed: shrinkage of the cells, condensation of
nuclear chromatin, and apoptotic bodies. On the right side of the
image we can observe necrotic changes to the HeLa cells (red
stained) when they have been treated with 2 IC50 concentrations
of compounds 2, 8, 11 and 12. Morphological evaluation of the
cell death indicated that these compounds have apoptotic effect
on the cells, and therefore should be a starting point for further
structural modifications in order to obtain more potent
compounds.
Modeling of biological activity
Quantitative structure–activity relationship (QSAR) studies relate
different molecular descriptors with their biological activities.
Molecular descriptors quantitatively encode the various molecular
features. They describe constitutional, topological, geometrical,
electrostatic, and quantum chemical characteristics of molecules.
The number of atoms and bonds in each molecule are connected
to the constitutional descriptors, the atomic connectivity in the
molecule to the topological descriptors, and the size of the mol-
ecule to geometrical descriptors. The electrostatic descriptors
reflect characteristics of the charge distribution of the molecule,
and the quantum chemical descriptors describes binding and for-
mation energies, partial atom charge, dipole moment, and
molecular orbital energy levels37. PLS (Partial Least Square) regres-
sion analysis is a commonly used statistical technique for perform-
ing multivariate calibration with the ability to analyse data sets
with a larger number of predictor variables than objects and in sit-
uations where there is more than one dependent variable38. In
order to derive PLS model which could help us in better under-
standing the mechanism of action of cyclic ureas and carbamates
(1–13), the biological activity expressed as logarithm of mean con-
centration of two measurements were used as dependent varia-
bles and molecular descriptors as the independent ones.
PLS modeling was performed on a large number of molecular
descriptors. Descriptors with variable importance in projection
scores (VIP) lower than 1 which are considered as irrelevant were
excluded from this set of molecular descriptors. Then, the final PLS
model was built only with descriptors with the VIP scores higher
than 1.
Compound 1 which showed the lowest anti-a-Gls activity was
excluded as the regression outlier. The obtained PLS model was
Figure 3. Cell survival rate diagram of compounds show survival of HeLa, A549 and MDA-MB-453 cells grown for 72 h in the presence of increasing concentrations of
investigated compounds.
Figure 4. Morphological changes observed on HeLa cells after 24 hours treatment
with IC50 and 2 IC50 concentrations of compounds dilutions. (A) Control; (B)
IC50, (C) 2 IC50 (supernatant) compound 2; (D) IC50, (E) 2 IC50 (supernatant)
compound 8; (F) IC50, (G) 2 IC50 (supernatant) compound 11; (I) IC50, (H) 2 IC50
(supernatant) compound 12; fluorescent microscope (PALM MicroBeamsystems,
Carl Zeiss, 20)
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statistically significant and resulted in two latent variables. The
statistical results, together with the descriptors included in the
final QSAR model with descending order of regression coefficients
with notification of the sign of their contribution on the depend-
ent variable are presented in Table 3. The plot of the measured
versus predicted retention parameters, plot of the variables versus
VIP scores, and plot of the coefficients of the model parameters
are given in Figure S1A–C (Supplemental Information).
According to the obtained PLS model, the most relevant
descriptors which influence the activity of examined cyclic ureas
and carbamates 1–13 are conformation-independent predicted
aqueous solubility (CIQPlogS), hydrophilic component of the total
solvent accessible surface area (FISA), Percent Human Oral
Absorption, predicted skin permeability (QPlogKp), predicted octa-
nol/water partition coefficient (QPlogPo/w), PM3 calculated ioniza-
tion potential (IP(eV)), predicted apparent MDCK cell permeability
(QPPMDCK). MDCK cells are considered to be a good mimic for
the blood–brain barrier. Molecular descriptors CIQPlogS, FISA, and
IP(eV) have positive sign of regression coefficients indicating that
higher these values are, the higher is their activity against a-Gls.
This is in accordance with the statment that when the drug passes
through the cell membrane and is found in intracellular fluid, it
has to be sufficiently water-soluble to achieve polar interactions
that allow their binding to the receptor site38. On the other hand,
molecular descriptors Percent Human Oral Absorption, QPlogKp,
QPlogPo/w, QPPMDCK, which encode hydrophobic interactions
influence the biological activity of both cyclic ureas 1–5 and car-
bamates 6–13 against a-Gls in the negative manner. These
descriptors are usually positively correlated with the lipophilicity
of the compound which influences the passage of molecules
through the cell membrane.
The obtained QSAR model can help us better understanding
the mechanism of action of examined cyclic ureas 1–5 and carba-
mates 6–13. These results can qualitatatively indicate the descrip-
tors that play an important role in the activity exhibited by similiar
compounds. From this preliminary model, we can assume that in
future synthesis of new compounds, the increase of their lipophi-
licity should be avoided, while on the other hand, introducing the
subsituents capable of participation in polar interactions with
active site on receptors into different positions of molecular struc-
ture would most likely enhance their activities.
Conclusions
In summary, the selected cyclic urea and carbamate derivatives
1–13 expressed significant in vitro inhibitory activity in the anti-
a-Gls activity study. All studied compounds showed higher anti
a-Gls activity (IC50 values from 49.85±0.10 to 104.06±0.65mM) than
the standard antidiabetic drug acarbose. Benzyl(3,4,5-trimethoxy-
phenyl)carbamate (12) was the most potent (IC50¼ 49.85±0.10mM)
when compared to acarbose (IC50¼ 121.01±12.18mM).
In vitro cytotoxic study of compounds 1–13 toward three
human cancer cell lines, HeLa, A549 and MDA-MB-453 indicated
moderate activities of compounds 2, 8, 11 and 12. Amongst
them trans-5-phenethyl-1-phenylhexahydro-1H-imidazo[4,5-c]pyridin-
2(3H)-one (2) was the most active against MDA-MB-453 cells
(IC50¼ 83.41mM). The other tested compounds expressed no
activity. Moreover, morphological evaluation of cells under the
fluorescent microscope revealed that apoptosis occurred after can-
cer cells were treated with IC50 concentrations of four, the most
active compounds (2, 8, 11 and 12), hence they should be further
investigated in the sense of structural modifications and cytotoxic
activity enhancement.
QSAR analysis was attempted on activity against a-Gls by
applaying PLS analysis. Obtained results qualitatively indicate the
descriptors playing an important role in the activity exhibited by
similiar compounds, thus suggesting that introduction of substitu-
ents able to form polar interactions with binding sites of receptor
while maintaining the lipophilicity would lead us to more active
structures, and thus helping us for planning the future synthesis.
This study demonstrated the promising anti-a-Gls activity of
cyclic ureas and carbamates. These derivatives will be the starting
point for synthesis of new analogues which will be further tested
as potential antidiabetic drugs.
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